[go: up one dir, main page]

MX2008001549A - 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis. - Google Patents

3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.

Info

Publication number
MX2008001549A
MX2008001549A MX2008001549A MX2008001549A MX2008001549A MX 2008001549 A MX2008001549 A MX 2008001549A MX 2008001549 A MX2008001549 A MX 2008001549A MX 2008001549 A MX2008001549 A MX 2008001549A MX 2008001549 A MX2008001549 A MX 2008001549A
Authority
MX
Mexico
Prior art keywords
psychoses
schizophrenia
cis
treatment
dihydrotetrabanezine
Prior art date
Application number
MX2008001549A
Other languages
English (en)
Inventor
Andrew John Duffield
Original Assignee
Cambridge Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd
Publication of MX2008001549A publication Critical patent/MX2008001549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona el uso de 3,11b-cis-dihidrotetrabenazina o una sal farmaceuticamente aceptable de la misma para la fabricacion de un medicamento para la profilaxis o tratamiento de la esquizofrenia y otras psicosis.
MX2008001549A 2005-08-06 2006-08-04 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis. MX2008001549A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
PCT/GB2006/002936 WO2007017654A1 (en) 2005-08-06 2006-08-04 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
MX2008001549A true MX2008001549A (es) 2008-04-04

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001549A MX2008001549A (es) 2005-08-06 2006-08-04 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.

Country Status (20)

Country Link
US (1) US20110257220A1 (es)
EP (2) EP1855677B1 (es)
JP (1) JP2009504622A (es)
KR (1) KR20080033500A (es)
AT (2) ATE534391T1 (es)
AU (1) AU2006277753B2 (es)
CA (1) CA2620960A1 (es)
CY (1) CY1108843T1 (es)
DE (1) DE602006004009D1 (es)
DK (1) DK1855677T3 (es)
ES (1) ES2318771T3 (es)
HR (1) HRP20090074T3 (es)
MX (1) MX2008001549A (es)
NZ (1) NZ566011A (es)
PL (1) PL1855677T3 (es)
PT (1) PT1855677E (es)
RS (1) RS50807B (es)
RU (1) RU2407743C2 (es)
SI (1) SI1855677T1 (es)
WO (1) WO2007017654A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
CN104744456A (zh) 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
JP6010108B2 (ja) 2011-04-01 2016-10-19 スリーエム イノベイティブ プロパティズ カンパニー トリアジン系紫外線吸収剤を含むフィルム
KR20160111999A (ko) 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
RU2757221C2 (ru) * 2014-02-07 2021-10-12 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
KR20190108146A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) * 1958-04-15 Quinolizine derivatives
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
ATE534391T1 (de) 2011-12-15
PT1855677E (pt) 2009-01-13
JP2009504622A (ja) 2009-02-05
EP1855677A1 (en) 2007-11-21
CA2620960A1 (en) 2007-02-15
RU2407743C2 (ru) 2010-12-27
EP2050451A1 (en) 2009-04-22
WO2007017654A1 (en) 2007-02-15
NZ566011A (en) 2011-01-28
US20110257220A1 (en) 2011-10-20
AU2006277753B2 (en) 2011-11-10
DE602006004009D1 (de) 2009-01-15
HK1111083A1 (en) 2008-08-01
EP1855677B1 (en) 2008-12-03
KR20080033500A (ko) 2008-04-16
CY1108843T1 (el) 2014-07-02
EP2050451B1 (en) 2011-11-23
ATE415968T1 (de) 2008-12-15
RS50807B (sr) 2010-08-31
DK1855677T3 (da) 2009-02-09
RU2008108623A (ru) 2009-09-20
PL1855677T3 (pl) 2009-07-31
AU2006277753A1 (en) 2007-02-15
HRP20090074T3 (en) 2009-04-30
SI1855677T1 (sl) 2009-04-30
ES2318771T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
MX2008001549A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.
TW200801006A (en) Fused bicyclic mTOR inhibitors
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TW200722100A (en) A therapeutic agent for a β related disorders
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IL193252A0 (en) N-hydroxyacrylamide compounds
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
MX2008001546A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de una enfermedad proliferativa o una inflamacion.
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2010001304A (es) Compuestos terapeuticos.
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
MY140538A (en) Substituted n-acyl-2-aminothiazoles
DE602007008947D1 (en) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
PL1924255T3 (pl) Zastosowanie N-(dibenz(b,f)oksepin-10-ylometylo)-N-metylo-N-prop-2-ynyloaminy (OMIGAPIL)
UA95085C2 (ru) Применение варденафила для лечения урологических расстройств

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights